CannPal Animal Therapeutics is a global leader in the development of innovative, cannabinoid-derived therapeutic products to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and more natural way.
Presently, the Company is developing products containing CBD, THC and other active ingredients for registration and commercialisation as veterinary medicines and nutraceuticals in the areas of pain, inflammation, mood and dermatological skin conditions.
CannPal is a subsidiary of AusCann Group Holdings (ASX:AC8) an Australian, Publicly listed company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. You can learn more about AusCann Group Holdings here